Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Nephrology | Urology | Family Medicine
Clinical Trials: Prostate Cancer
A listing of clinical trials currently looking for volunteers to enroll in Prostate Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Birmingham :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Homewood :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Muscle Shoals : Investigational Site Number 840002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Muscle Shoals : Investigational Site Number 840004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Alaska
Anchorage :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Arizona
Phoenix : Precision Trials, LLC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Phoenix : Caris Science, Inc.
EMBRACE1: Prostate Biorepository
Phoenix : Foundation for Cancer Research and Education
SpaceOAR System Pivotal Study
Phoenix :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Phoenix, Mesa, Scottsdale, Glendale : Arizona Oncology Services Foundation
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
View More »
Scottsdale : 21st Century Oncology
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Scottsdale :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Scottsdale :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Scottsdale :
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Scottsdale : Pinnacle Oncology
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
Tucson :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Tucson :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Tucson : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Tuscon :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Arkansas
Hot Springs : Investigational Site Number 840004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hot Springs : Investigational Site Number 840002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
California
Duarte : City of Hope
A Prospective Randomized Trial of Pelvic Drain Placement Versus no Pelvic Drain Placement After Robotic Assisted Laparoscopic Prostatectomy (RALP) in Patients with Prostate Cancer
Duarte : City of Hope
A Randomized, Phase II Study, Assessing Axitinib as Pre-Surgical Therapy in Patients with High Risk Prostate Cancer
Duarte : City of Hope
Assessment of Change in Peripheral pStat3 Levels, Circulation Tumor Cells and MDSC Quanity in High Risk Prostate Cancer Pre-and Post Prostatectomy
Duarte : City of Hope
Assessment of Changes in Inflammatory Cytokines and Downstream Mediators of Prostate Carcinogenesis in Patients Receiving Radiation Therapy for Localized Prostate Cancer
Duarte : City of Hope
Assessment of the Relationship Between Changes in PSA and Peripheral pStat3 Levels, MDSC Quantity and VKOR Mutation in Castrate Resistant Prostate Cancer
Duarte : City of Hope
Long Term Follow Up after Prostate Cancer
Duarte : City of Hope
Prostate Cancer Database
View More »
Anaheim : Investigational Site Number 840008
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Anaheim : Investigational Site Number 840009
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Anaheim :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Atherton : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Bakersfield : Investigational Site Number 840014
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Baldwin Park :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Beverly Hills : Westside Prostate Cancer Center, University of Southern California
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Campbell : Urological Surgeons of Northern California
SpaceOAR System Pivotal Study
Escondido : San Diego Radiosurgery at Palomar Medical Center
Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer
Fontana :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Hayward :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Highland :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
La Mesa : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Laguna Hills : South Orange County Medical Research Center
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
Long Beach : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Los Angeles : University of California, Los Angeles Institute of Urologic Oncology
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Los Angeles : University of Southern California
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Los Angeles :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Los Angeles : Tower Urology / Tower Research Institute
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Los Angeles : David Geffen School of Medicine at UCLA
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Los Angeles :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Los Angeles : USC/Norris Comprehensive Cancer Center
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Los Angeles :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Marina Del Rey : Prostate Oncology Specialists
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Marina del Rey :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Marina del Rey :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Modesto : Investigational Site Number 840030
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Murrieta : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Oakland :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Orange :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Orange : Chao Comprehensive Cancer Center
Trail of Taxotere Plus Sunitinib on Newly Diagnosed, Hormone Refractory, Metastatic Prostate Cancer
Palo Alto :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Rancho Mirage :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Roseville :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Sacramento : University of California Davis Cancer Center
Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
Sacramento :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Sacramento : Radiological Associates of Sacramento
SpaceOAR System Pivotal Study
Sacramento : University of California at Davis
Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer
San Bernardino : San Bernardino Urological Associates Updated
A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
San Bernardino : Investigational Site Number 840001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
San Bernardino : Investigational Site Number 840003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
San Bernardino :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
San Diego : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
San Diego : Genesis Research
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
San Diego :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
San Diego :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
San Diego :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
San Diego : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
San Francisco :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
San Francisco : University of California, San Francisco
Abiraterone Post Ketoconazole for Prostate Cancer
San Francisco : Investigational Site Number 840010
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
San Francisco : Investigational Site Number 840012
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
San Francisco :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
San Francisco : University of California, San Francisco
Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC
San Francisco :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
San Francisco :
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
San Jose :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
San Luis Obispo : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
San Marcos :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
San Marcos :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Santa Clara :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
South San Francisco :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Stockton : Investigational Site Number 840022
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Torrance :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Vallejo :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Walnut Creek :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Colorado
Denver : The Urology Center of Colorado
A Phase 4, placebo controlled study to evaluate the efficacy and safety of VESIcare to improve urinary incontinence in men after robotic assisted radical prostatectomy
Denver : The Urology Center of Colorado
A Phase 4, placebo controlled study to evaluate the efficacy and safety of VESIcare to improve urinary incontinence in men after robotic assisted radical prostatectomy
Denver : The Urology Center of Colorado
A Phase II study of Abiraterone Acetate plus Prednisone in subjects with advanced prostate cancer without radiographic evidence of metastatic disease
Denver : The Urology Center of Colorado
International, open label, randomized study assessing the safety and efficacy of a monthly dosing regimen of Ozarelix vs. Goserlin Depot (Zoladex) in men with prostate cancer.
Denver : The Urology Center of Colorado
Open, non-randomized, uncontrolled, multiple dose escalation study of the safety and effectiveness of an investigational drug (ODM-201) for men with advanced prostate cancer.
Denver : The Urology Center of Colorado
Phase 2 multicenter prospective open label, 2- dose level clinical trial studying the safety and efficacy of an injection of NX-1207 for the treatment of low risk, localized (T1c) prostate cancer.
Denver : The Urology Center of Colorado
Phase II efficacy and safety study of MDV3100 vs. bicalutamide in castrate men with metastatic prostate cancer
Denver : The Urology Center of Colorado
Phase II, double blind, efficacy and safety study of Enzalutamide vs. Bicalutamide in men with prostate cancer who have failed primary androgen deprivation therapy.
Denver : The Urology Center of Colorado
Study to Evaluate New or Worsening Lens Opacifications in Subjects with Nonmetastatic
Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy
View More »
Aurora :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Aurora : University of Colorado Hospital
Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer
Aurora : University of Colorado Cancer Center
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
Aurora :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Boulder : Rocky Mountain Cancer Center
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Denver : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Denver : Investigational Site Number 840019
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Denver :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Denver : The Urology Center of Colorado
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Denver :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Denver : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Englewood : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Littleton :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Wheat Ridge : The Urology Center of Colorado
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Wheat Ridge : The Urology Center of Colorado
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Connecticut
Hartford : Investigational Site Number 840031
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Middlebury : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
New Britain : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
New Britain : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Norwich : Eastern CT Hematology and Oncology Associates
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
View More »
Norwich : Eastern CT Hematology and Oncology Associates
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Stamford : Investigational Site Number 840021
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Stamford : Investigational Site Number 840029
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Delaware
Newark : Helen F. Graham Cancer Center
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
District of Columbia
Washington :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Florida
Aventura : South Florida Medical Research
Metastatic, Androgen-Independent study for patients with Prostate Cancer
Aventura : South Florida Medical Research, Inc.
Phase IV, Hormone Refractory Prostate Cancer Study
Fort Lauderdale : Holy Cross Hospital
AT13387-04
Fort Lauderdale : Holy Cross Hospital
ECOG E3805
Naples : Specialists in Urology
A multicenter clinical study of the Sonablate 500 for the treatment of locally recurrent prostate cancer with HIFU
Tallahassee : Southeastern Research Group, Inc.
Prostate Cancer - A Phase III, Open-Label Trial of Degarelix Intermittent Therapy vs. Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in patients with carcinoma of the prostate with biochemical failure after localized therapy
Tampa : H. Lee Moffitt Cancer Center & Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Aventura :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Aventura : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Boca Raton : Investigational Site Number 840013
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Boca Raton :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Bradenton : Lakewood Ranch Oncology Center/21st Century Oncology
SpaceOAR System Pivotal Study
Daytona Beach : Atlantic Urological Associates
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Daytona Beach :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Fort Lauderdale : Holy Cross Hospital
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Fort Meyers : 21st Century Oncology
SpaceOAR System Pivotal Study
Fort Myers : 21st Century Oncology
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Jacksonville : Investigational Site Number 840023
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Jacksonville : Investigational Site Number 840035
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Jacksonville :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Lakeland : Lakeland Regional Cancer Center
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Lakeland : Investigational Site Number 840013
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Naples :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Naples : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Ocala : Urology Health Team
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Orange City : Atlantic Urological Associates
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Orange City :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Orange City :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Orlando : MD Anderson-Orlando-Orlando Health
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Orlando : Winter Park Urology Associates, PA
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Orlando :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Port St. Lucie : Investigational Site Number 840003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Port St. Lucie : Investigational Site Number 840001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Sarasota : Florida Urology Specialists
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Sarasota :
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
Trinity : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Wellington :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
West Palm Beach :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Georgia
Athens :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Atlanta :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Atlanta : Emory University
SpaceOAR System Pivotal Study
Atlanta :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Marietta : Georgia Cancer Specialists, P.C.
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
View More »
Marietta :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Idaho
Coeur d'Alene : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Coeur d'Alene : North Idaho Urology
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Meridian : Idaho Urologic Institute
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Illinois
Elgin : Sherman Health
ECOG E2809 Phase II Randomized Study of Bicalutamide With Versus Without Akt Inhibitor MK2206 in Patients With Prostate Cancer and Rising PSA at High-Risk of Progression After Primary Therapy
Elgin : Sherman Health
ECOG E3805 Phase III Randomized Study of Chemohormonal Therapy Versus Androgen-Ablation Therapy in Patients With Extensive Metastatic Prostate Cancer
Elgin : Sherman Health
SWOG S0925 Phase II Randomized Study of Combined Androgen Deprivation Comprising Bicalutamide and Goserelin or Leuprolide Acetate With Versus Without Cixutumumab in Patients With Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer
Elgin : Sherman Health
SWOG S1014 Phase II Study of Abiraterone Acetate in Patients With Metastatic Prostate Cancer and a Sub-Optimal Prostate-Specific Antigen Following Initial Androgen-Deprivation Therapy
Elk Grove Village : Alexian Brothers Hospital Network
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.
View More »
Chicago :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
Chicago : University of Chicago
Abiraterone Post Ketoconazole for Prostate Cancer
Chicago : The University of Chicago
Pazopanib, Docetaxel, Prednisone Prostate
Chicago : Northwestern University
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
Chicago :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Decatur : Investigational Site Number 840015
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Evanston :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Evanston : North Shore University
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
Galesburg :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Galesburg :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Glenview :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Maywood : Pfizer Investigational Site
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Melrose Park : Uropartners/RMD Clinical Research
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Melrose Park :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Niles : Oncology Specialists, SC
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Niles : Oncology Specialists, S.C
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
Niles :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Park Ridge : Oncology Specialists, S.C.
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Park Ridge : Oncology Specialists, S.C
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
Springfield : Southern Illinois University School of Medicine
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Indiana
Greenwood : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Indianapolis : Indiana University School of Medicine
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Indianapolis :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Jeffersonville : First Urology
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Jeffersonville :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
View More »
Jeffersonville :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Jeffersonville : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Iowa
West Des Moines : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kansas
Overland Park : Kansas City Urology Care, PA
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Westwood :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Wichita : Investigational Site Number 840018
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Wichita : Cancer Center of Kansas
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Wichita :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Kentucky
Paducah : Investigational Site Number 840010
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Louisiana
Matairie :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
New Orleans : Investigational Site Number 840007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
New Orleans : Investigational Site Number 840008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
New Orleans :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
New Orleans : Tulane University
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
View More »
New Orleans :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Shreveport : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Shreveport :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Shreveport : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Maryland
Annapolis : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Annapolis : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Baltimore : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Baltimore : Johns Hopkins University
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Baltimore : Investigational Site Number 840014
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
View More »
Baltimore : The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Baltimore : Johns Hopkins Medical Institutions
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
Baltimore : Johns Hopkins University Department of Radiation Oncology and Molecular Radiation Sciences
SpaceOAR System Pivotal Study
Baltimore :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Baltimore : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Bethesda : Center for Cancer & Blood Disorders
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
Bethesda : Walter Reed National Military Medical Center
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Bethesda :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Greenbelt : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Greenbelt : Mid Atlantic Clinical Research
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Owings Mills : Chesapeake Urology Associates, Chesapeake Urology Research Associates (The Prostate Center)
SpaceOAR System Pivotal Study
Rockville : Investigational Site Number 840005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Rockville : Investigational Site Number 840006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Rockville :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Towson :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Massachusetts
Boston : Dana-Farber Cancer Institute
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Boston : Beth-Israel Deaconess Medical Center
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Boston : Investigational Site Number 840238
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Boston : Investigational Site Number 840138
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Boston : Boston University Medical Center
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
View More »
Boston : Dana-Farber Cancer Institute and (Sanofi-Aventis Consortium)
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Boston :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Boston : Beth Israel Deaconess Medical Center
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
Boston : Dana-Farber Cancer Institute
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
Boston : Massachusetts General Hospital
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
Boston : Massachusetts General Hospital Cancer Center
Safety Study of MGA271 in Refractory Cancer
Boston :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Boston :
Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Brookline : Investigational Site Number 840038
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Rockland : Contact US Medical Information in Rockland, MA for US Recruiting Sites
L-BLP25 (Stimuvax) in Prostate Cancer
Worcester : University of Massachusetts Medical School
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Michigan
Ann Arbor : University of Michigan
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Ann Arbor : University of Michigan Comprehensive Cancer Center
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
Ann Arbor : University of Michigan Health System
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Detroit :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
Detroit : Karmanos Cancer Institute
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Detroit : Investigational Site Number 840005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Detroit : Karmanos Cancer Institute
Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
Detroit : Wayne State (Karmanos Cancer Institute)
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
Detroit :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Detroit :
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Detrot :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Lansing :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Troy :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Minnesota
Minneapolis :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Rochester : Mayo Clinic
A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology
Sartell : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
St Louis Park : Investigational Site Number 840017
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
St Louis Park : Investigational Site Number 840021
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Mississippi
Jackson : Investigational Site Number 840011
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Missouri
Jefferson City :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Kansas City : Investigational Site Number 840016
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
St Louis : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
St. Louis : Washington University School of Medicine
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
St. Louis :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
View More »
St. Louis :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Montana
Billings : Frontier Cancer Center and Blood Institute
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Nebraska
Lincoln : Investigational Site Number 840016
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lincoln : Investigational Site Number 840020
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lincoln :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Omaha : Urology Cancer Center and GU Research Network Updated
A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
Omaha : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
View More »
Omaha : Urology Cancer Center and GU Research Network
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Omaha :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Omaha :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Omaha : University of Nebraska Medical Center
SpaceOAR System Pivotal Study
Omaha : Urology Cancer Center, PC
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer
Omaha :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Nevada
Las Vegas :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
New Jersey
Lawrenceville : AdvanceMed Research
A Clinical Research Study for Advanced Prostate Cancer is Currently Enrolling
Lawrenceville : AdvanceMed Research
Prostate Cancer that requires Hormone therapy.
View More »
Berlin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brick : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
East Orange : Department Of Veterans Affairs NJ Health Care System
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
East Orange : Department of Veterans Affairs NJ Health Care System
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
East Orange : Investigational Site Number 840015
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
East Orange : Investigational Site Number 840017
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Englewood : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Freehold : CentraState Medical Center
SpaceOAR System Pivotal Study
Hamilton : Premier Urology Associates, LLC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Lawrenceville : Premier Urology Associates, LLC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Lawrenceville :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Mount Laurel : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
New Brunswick : Cancer Institute of New Jersey
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
New Brunswick : The Cancer Institute of New Jersey
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
New Brunswick : The Cancer Institute of New Jersey
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
New Brunswick : The Cancer Institute of New Jersey
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Voorhees : Cooper University Hospital
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Voorhees : Delaware Valley Urology
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Voorhees : Delaware Valley urology, LLC
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Voorhees : Delaware Valley urology, LLC
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
New Mexico
Albuquerque : Urology Group of New Mexico
Prostate Cancer with/without bone metastasis
View More »
Albuquerque : Investigational Site Number 840033
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Albuquerque : University of New Mexico Cancer Center
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Albuquerque : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
New York
Bronx : Biomedical Research Alliance of New York
Prostate Cancer - Adult Men
Bronx : Biomedical Research Alliance of New York
Prostate Cancer - Adults
Garden City : Advanced Urology Centers of New York, Garden City Central Research Department
For Men with Non-Metastatic Prostate Cancer: A Clinical Trial That Might Interest You
Garden City : Advanced Urology Centers of New York, Garden City Central Research Department
Phase 2, MultiCenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the treatment of Low Risk, Localized (T1c) Prostate Cancer
View More »
Albany : The Urological Institute of Northeastern New York
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Albany :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Albany :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Brooklyn : Brooklyn Urology Research Group
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Brooklyn :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Buffalo :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Buffalo :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Erie, Niagara, and Chautauqua County : Western New York Urology Associates, LLC and D/B/A Cancer Care of WNY
SpaceOAR System Pivotal Study
Garden City : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Garden City :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Garden City :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Garden City :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Garden City : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Lake Success : Monter Cancer Center
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Lake Success : North Shore University Hospital-Monter Cancer Center
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
Lake Success : Advanced Radiation Centers of New York
SpaceOAR System Pivotal Study
New Hyde Park : The Arthur Smith Institute for Urology
MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer
New York : Memorial Sloan-Kettering Cancer Center
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
New York : New York Presbyterian Hospital, Weill Cornell Medical College
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
New York :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
New York : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
New York : Memorial Sloan-Kettering Cancer Center
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
New York : Investigational Site Number 840022
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
New York : Investigational Site Number 840034
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
New York : Memorial Sloan Kettering Cancer Center
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
New York : Memorial Sloan Kettering Cancer Center
Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
New York : University Urology Associates
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
New York :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
New York : Memorial Sloan-Kettering Cancer Center
Molecular Studies and Clinical Correlations in Human Prostatic Disease
New York : Memorial Sloan Kettering Cancer Center
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
New York : Memorial Sloan-Kettering Cancer Center
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
New York : NYU Cancer Center
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
New York :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
New York : Memorial Sloan-Kettering Cancer Center
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
New York : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Poughkeepsie : The Premier Medical Group of the Hudson Valley, PC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Poughkeepsie :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Poughkeepsie :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Rochester : University of Rochester
SpaceOAR System Pivotal Study
Staten Island : Staten Island Urological Research, PC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Staten Island :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Syracuse : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Syracuse :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Syracuse : Associated Medical Professionals of NY
SpaceOAR System Pivotal Study
Syracuse : Upstate Medical University
SpaceOAR System Pivotal Study
Tarrytown : Progenics Pharmaceuticals, Inc
A Study of PSMA ADC in Subjects With Castration-resistant Metastatic Prostate Cancer
Tarrytown : Progenics Pharmaceuticals, Inc.
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
North Carolina
Charlotte : USHIFU
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)
Durham : Duke University
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
Salisbury : PMG Research of Salisbury
Would you like to help develop a new test for the detection of prostate cancer?
Winston-Salem : PMG Research of Winston-Salem
Would you like to help develop a new test for the detection of prostate cancer?
View More »
Chapel Hill :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Concord :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Durham : Duke Cancer Institute
BKM120 in Metastatic Castration-resistant Prostate Cancer
Durham : Duke Cancer Institute
Pazopanib, Docetaxel, Prednisone Prostate
Durham : Duke University
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
Durham :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Greensboro : Moses Cone Regional Cancer Center
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Greensboro :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Greenville : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Raleigh : Investigational Site Number 840024
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Raleigh : Investigational Site Number 840036
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Raleigh :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Raleigh :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Raleigh :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Washington : Investigational Site Number 840011
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Wilmington : PMG Research of Wilmington
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Winston Salem : PMG Research of Winston Salem
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
North Dakota
Bismarck : St. Alexius Medical Center
A research study for patients who have been diagnosed with metastatic, castrate-resistant prostate cancer
Bismarck : Legacy Pharma Research
Prostate Cancer
View More »
Bismarck :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Bismark :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Ohio
Akron : Investigational Site Number 840020
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Akron : Investigational Site Number 840026
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Blue Ash : Oncology Hematology Care, Inc.
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Cincinati :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Cincinnati :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
View More »
Cleveland : Investigational Site Number 840023
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Cleveland :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Cleveland :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Cleveland : Cleveland Clinic
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Cleveland : Cleveland Clinic
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Cleveland : University Hospitals Case Medical Center
SpaceOAR System Pivotal Study
Cleveland :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Oregon
Portland : OHSU Knight Cancer Institute
BKM120 in Metastatic Castration-resistant Prostate Cancer
Portland : Oregon Health and Science University
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Portland : Oregon Health and Science University Cancer Institute
Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC
Portland : Oregon Health & Science University
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
Portland : Oregon Health & Science University
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
View More »
Springfield :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Pennsylvania
Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania
A randomized, double-blind, parallel, placebo-controlled, phase 4, multicenter study to assess efficacy and safety of Vesicare® (solifenacin succinate) to improve urinary continence of subjects after robotic assisted radical prostatectomy. Clinical trial NCT01371994.
Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania
A randomized, double-blind, phase 2, efficacy and safety study of MDV3100 versus bicalutamide in castrate men with metastatic prostate cancer. Clinical trial NCT01288911.
Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania
A randomized, double-blind, phase 3 efficacy trial of PROSTVAC-V/F +/- GM-CSF in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Clinical trial NCT01322490.
Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania
This is a double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in subjects with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen-deprivation therapy. Clinical trial NCT00925600.
Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania
This is an open-label study of the effect of GTx-758 as a secondary hormone therapy on serum PSA and serum free testosterone levels in men with metastatic castration-resistant prostate cancer maintained on androgen deprivation therapy. Clinical trial NCT01615120.
View More »
Bala Cynwyd : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Bala Cynwyd : Urologic Consultants of SE PA
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Bryn Mawr : Urology Health Specialists, LLC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Dunmore : Investigational Site Number 840032
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lancaster : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Lancaster :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Lancaster :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Lancaster :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Philadelphia : Thomas Jefferson University / Jefferson Urology Associates
A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology
Philadelphia : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Philadelphia : Thomas Jefferson University
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Philadelphia :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Philadelphia : Thomas Jefferson University
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Philadelphia : Fox Chase Cancer Center
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Philadelphia :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center
Safety Study of MGA271 in Refractory Cancer
Pittsburgh :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Pittsburgh :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
State College :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Rhode Island
Pawtucket : Investigational Site Number 840006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Pawtucket : Investigational Site Number 840007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
South Carolina
Charleston : Medical University of South Carolina
A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology
Charleston : Medical University of South Carolina
Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Columbia : South Carolina Oncology Associates
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Greenville : Greenville Hospital System University Medical Center Updated
A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
Greenville :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
View More »
Greenville :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Greer : Matrix Research, LLC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Myrtle Beach : Investigational Site Number 840037
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Myrtle Beach : Carolina Urologic Research Center
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Myrtle Beach :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Myrtle Beach :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Myrtle Beach : Carolina Urologic Research Center
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Myrtle Beach : Carolina Urologic Research Center
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Myrtle Beach : 21st Century Oncology
SpaceOAR System Pivotal Study
Myrtle Beach : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
South Dakota
Watertown :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Tennessee
Bristol : PMG Research of Bristol
Would you like to help develop a new test for the detection of prostate cancer?
Nashville : Sarah Cannon Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Chattanooga : Investigational Site Number 840025
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Chattanooga : Investigational Site Number 840028
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Chattanooga : Chattanooga Oncology and Hematology Associates
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Germantown : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Knoxville : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nashville : Tennessee Oncology, PLLC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Nashville : Urology Associates, PC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Nashville :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Nashville :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Nashville : Sarah Cannon Research Institute
Safety Study of MGA271 in Refractory Cancer
Nashville :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Nashville :
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Nashville : Vanderbilt University
Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
Texas
Amarillo :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Austin : The Hospital at Westlake Medical Center
Real Time Microscopic Imaging During Robot Assisted Prostate Cancer Surgery
Bedford :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Carrollton : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Corpus Christi : Investigational Site Number 840012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
View More »
Dallas : Urology Clinics of North Texas
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Dallas :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Dallas :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Ft. Worth : Center for Cancer and Blood Disorders, PC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Houston : University of Texas Vanguard Urologic Research Foundation
A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology
Houston : The University of Texas M D Anderson Cancer Center
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Houston : UT MD Anderson Cancer Center
Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy
Houston : UT MD Anderson Cancer Center
Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer
Houston : UT MD Anderson Cancer Center
Maximum Androgen Depletion
Houston : UT MD Anderson Cancer Center
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Houston : UT MD Anderson Cancer Center
Neoadjuvant Axitinib in Prostate Cancer
Houston : UT MD Anderson Cancer Center
Neoadjuvant Ipilimumab in Prostate Cancer
Houston : UT MD Anderson Cancer Center
Prostate Conformal Cryotherapy
Houston :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Houston : UT MD Anderson Cancer Center
TKI258 in Castrate Resistant Prostate Cancer
Houston and Lubbock : Advanced Research Network
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Laredo :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Round Rock :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
San Antonio : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
San Antonio : Urology San Antonio Research, PA
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
San Antonio : Urology San Antonio Research
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
San Antonio : Urology of San Antonio Research
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
San Antonio :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
San Antonio :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Tomball : Texas Urology Specialists
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Utah
Salt Lake City :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Salt Lake City :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Salt Lake City : For information concerning this clinical site, please contact Nymox at 800-936-9669.
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Virginia
Fairfax : Virginia Cancer Specialists, PC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Fairfax :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Newport News :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Norfolk :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Richmond : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
View More »
Richmond : Virginia Cancer Institute
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Richmond :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Salem : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Virginia Beach : Urology of Virginia
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Virginia Beach :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Virginia Beach : Urology of Virginia, PLLC
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Virginia Beach : Urology of Virginia, PLLC
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Virginia Beach : Urology of Virginia
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
Washington
Seattle : University of Washington- Seattle Cancer Care Alliance
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Burien : Seattle Urology Research Center
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Poulsbo : Peninsula Cancer Center
SpaceOAR System Pivotal Study
Seattle : University of Washington School of Medicine
A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology
Seattle :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
Seattle : Group Health Cooperative
I-125 Versus Pd-103 for Medium Risk Prostate Cancer
Seattle : VA Puget Sound
I-125 Versus Pd-103 for Medium Risk Prostate Cancer
Seattle : University of Washington
Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC
Seattle : Seattle Cancer Care Alliance
Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy
Seattle :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Seattle : Virginia Mason Hospital
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
Seattle : Virginia Mason Medical Center
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
Seattle :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Seattle :
Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Spokane :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Wisconsin
Madison : University of Wisconsin
A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology
Madison : Updated
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Madison : University of Wisconsin Carbone Cancer Center
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Madison : University of Wisconsin Carbone Cancer Center
Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
Madison : University of Wisconsin Carbone Cancer Center
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
View More »
Madison :
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Madison :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Madison : University of Wisconsin Carbone Cancer Center
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Milwaukee :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Argentina
Buenos Aires : Investigational Site Number 032002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Rosario : Investigational Site Number 032001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Salta : Investigational Site Number 032003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Santa Fe : Investigational Site Number 032004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Australia
Adelaide : Investigational Site Number 036014
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bankstown : Investigational Site Number 036013
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bankstown : Investigational Site Number 036016
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Box Hill : Investigational Site Number 036010
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Brisbane : Haematology and Oncology Clinics of Australia
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
View More »
Camperdown : Investigational Site Number 036012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Camperdown : Investigational Site Number 036008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Coffs Harbour : Investigational Site Number 036008
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Coffs Harbour : Investigational Site Number 036015
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Concord : Investigational Site Number 036001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Concord : Investigational Site Number 036001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Darlinghurst : St Vincent's Hospital, Sydney
A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer
Elizabeth Vale : Investigational Site Number 036015
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Fitzroy : Investigational Site Number 036009
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Fitzroy : Investigational Site Number 036017
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Garran : Investigational Site Number 036007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Heidelberg West : Investigational Site Number 036005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Herston : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Herston : Investigational Site Number 036003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Hobart : Royal Hobart Hospital
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Hobart :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Hornsby : Investigational Site Number 036010
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Kogarah : St George Public Hospital
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Kurralta Park : Investigational Site Number 036012
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Kurralta Park :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Malvern : Investigational Site Number 036002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Milton :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Parkville : Investigational Site Number 036002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Port Macquarie :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Randwick :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Richmond : Epworth Healthcare
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Ringwood East : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
South Brisbane : Investigational Site Number 036006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
South Brisbane : Investigational Site Number 036009
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Subiaco : Investigational Site Number 036016
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Subiaco : Investigational Site Number 036011
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Toowoomba : Radiation Oncology Queensland
PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)
Wahroonga : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Wahroonga : Investigational Site Number 036003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Wahroonga :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Westmead : Westmead Hospital
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Wodonga : Investigational Site Number 036004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Wodonga : Investigational Site Number 036013
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Woodville South : The Queen Elizabeth Hospital
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Austria
Graz : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Salzburg :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
St Poelten : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wels : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Wien : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wien :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Belarus
Gomel : Investigational Site Number 112003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Minsk : Investigational Site Number 112001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Minsk : Investigational Site Number 112002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Vitebsk : Investigational Site Number 112004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Belgium
Aalst : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aalst : Onze-Lieve-Vrouwziekenhuis
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Antwerpen : Investigational Site Number 056007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bonheiden : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasschaat : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Brugge : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brugge : Investigational Site Number 056015
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Brugge : AZ Sint-Jan AV
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Brussel : Investigational Site Number 056008
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Brussels :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Bruxelle : Hôpital Erasme
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bruxelles : Investigational Site Number 056001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bruxelles : Investigational Site Number 056002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bruxelles : Université Catholique de Louvain
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Charleroi : Investigational Site Number 056009
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Edegem : Investigational Site Number 056014
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Eupen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gent : Investigational Site Number 056003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Gent : UZ Gent
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Gent : AZ Maria Middelares
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Ghent : University Hospital Ghent
The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate
Gilly : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Haine-Saint-Paul : Investigational Site Number 056016
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hasselt : Investigational Site Number 056005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Ieper : Regionaal Ziekenhuis Jan Yperman VZW
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kortrijk : AZ Groeninge - Campus Sint-Maarten
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Leuven : University Hospitals Leuven
A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology
Libramont : Investigational Site Number 056010
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Liège : Investigational Site Number 056013
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Liège : CHU de Liège
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Liège :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Mechelen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Namur : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oostende : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oostende : AZ Damiaan
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Ottignies : Investigational Site Number 056011
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Roeselare : Investigational Site Number 056004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Roeselare :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Sint-Niklaas : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Turnhout : Investigational Site Number 056006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Verviers : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Yvoir : Investigational Site Number 056012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bosnia and Herzegovina
Sarajevo : Klinicki Centar Univerziteta Sarajevo - Klinika za gastroenterohepatologiju
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
Brazil
Curitiba : Investigational Site Number 004
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Fortaleza : Investigational Site Number 076016
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Ijui : Investigational Site Number 076012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Mogi Das Cruzes : Investigational Site Number 076015
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Passo Fundo : Investigational Site Number 076006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Porto Alegre : Investigational Site Number 076014
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Porto Alegre : Investigational Site Number 076001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Porto Alegre : Investigational Site Number 076002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Rio De Janeiro : Investigational Site Number 076010
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Rio De Janeiro : Investigational Site Number 076004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Rio de Janeiro : Multi-Imagem and CDPI - Clínica de Diagnóstico por Imagem
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Salvador : Investigational Site Number 076007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Santo Andre : Investigational Site Number 001
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Sao Jose Do Rio Preto : Investigational Site Number 076003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Jose Do Rio Preto : Investigational Site Number 076009
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076013
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076008
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076009
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
São Paulo : Investigational Site Number 002
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Uberlandia : Investigational Site Number 076003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Bulgaria
Plovdiv : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Sofia : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Canada
Toronto, Ontario : Princess Margaret Hospital
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Abbotsford : Dr. George Vrabec
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Abbottsford : Site Ref # / Investigator 56448
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Barrie : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Barrie : The Male/Female Health and Research Centre
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Barrie : Site Ref # / Investigator 56450
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Brampton : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brampton : Dr. Stanley Flax
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Brampton : Dr. Jonathan Giddens
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Brampton : Site Ref # / Investigator 54902
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Brantford : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brantford : Brantford Urology Research
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Brantford : Site Ref # / Investigator 54543
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Burlington : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Burlington : G. Kenneth Jansz Medicine Professional Corporation
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Burlington : Site Ref # / Investigator 57123
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Burlington : Site Ref # / Investigator 54904
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Calgary : Tom Baker Cancer Centre
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Chicoutimi : Site Ref # / Investigator 57032
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Edmonton : Cross Cancer Institute
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Edmonton :
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
Edmonton : Cross Cancer Institute
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Edmonton : Cross Cancer Institute
Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences
Gatineau : Hôpital de Gatineau
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Granby : Site Ref # / Investigator 55512
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Greenfield Park : Investigational Site Number 124002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Greenfield Park : Urology South Shore Research
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Greenfield Park : Urology South Shore Research Inc.
Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year
Greenfield Park : Site Ref # / Investigator 56447
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Guelph : Dr. Eric Hirshberg
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Guelph : Site Ref # / Investigator 56452
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Halifax : QEII Health Sciences Center
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Halifax : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Hamilton : Juravinski Cancer Centre at Hamilton Health Sciences
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Hamilton : Juravinski Cancer Centre
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Hamilton : Juravinski Cancer Centre
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
Kelowna : BCCA - Cancer Centre for the Southern Interior
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Kelowna : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kelowna : BC Cancer Agency - Centre for Southern Interior
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
Kelowna : Southern Interior Medical Research Inc.
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Kelowna : Site Ref # / Investigator 56446
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Kingston : Cancer Centre of Southeastern Ontario at Kingston
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Kitchener : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Laval : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Laval : Polyclinique Med Concorde
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Laval : Site Ref # / Investigator 54903
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
London : London Regional Cancer Program
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
London : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
London : Investigational Site Number 124002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
London : Site Ref # / Investigator 54907
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
London : London Regional Cancer Program
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
London :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Mississauga : Investigational Site Number 124007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Moncton : Investigational Site Number 124005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Montreal : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Montreal : CHUM-Notre- Dame
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Montreal : Hôpital Maisonneuve-Rosemont
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Montreal : Jewish General Hospital
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Montreal : Investigational Site Number 124003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Montréal : CHUM-Hospital Notre-Dame
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Newmarket : Dr. Morrie Liquornik
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Newmarket : Site Ref # / Investigator 54909
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
North York : Toronto Urology Clinical Study Group
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
North York : Site Ref # / Investigator 54908
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Oakville : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Oakville : Dr. Richard Casey
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Oakville : Site Ref # / Investigator 54542
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Oshawa : Investigational Site Number 124001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Oshawa : R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Ottawa : Investigational Site Number 124003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Owen Sound : Investigational Site Number 124005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Owen Sound : Dr. Todd Webster
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Owensound : Site Ref # / Investigator 56449
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Peterborough : Site Ref # / Investigator 61722
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Peterborough : Site Ref # / Investigator 56917
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Pointe-Claire : Site Ref # / Investigator 56445
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Quebec : Investigational Site Number 124004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Quebec : CHUQ- Hotel-Dieu de Quebec
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
Regina : Allan Blair Cancer Centre
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Scarborough : Dr. Allan Abramovitch
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Scarborough : Site Ref # / Investigator 54905
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Sherbrooke : CHUS - Hôpital Fleurimont - Sherbrooke
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Surrey : Andreou Research
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Surrey : Site Ref # / Investigator 56443
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Toronto : Univ. Health Network-Princess Margaret Hospital
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Toronto : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Toronto : Investigational Site Number 124006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Toronto : Sunnybrook Health Sciences Centre
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Toronto : Sunnybrook Health Sciences Centre
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
Toronto : Site Ref # / Investigator 56451
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Toronto : Site Ref # / Investigator 57762
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Toronto : Site Ref # / Investigator 60843
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Toronto : Site Ref # / Investigator 56444
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Toronto :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Toronto :
Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Trois-Rivieres : Site Ref # / Investigator 56453
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Trois-Rivières : Centre Hospitalier régional de Trois-Rivières
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Val d'Or : Site Ref # / Investigator 55513
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Vancouver : BCCA - Vancouver Cancer Centre
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Vancouver :
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
Vancouver : British Columbia Cancer Agency
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Vancouver : BC Cancer Agency - Vancouver Centre
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
Vancouver : BC Cancer Agency
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Vancouver : BCCA - Vancouver Cancer Centre
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Vancouver :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Vancouver :
Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Victoria : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Victoria : Dr. Steinhoff Clinical Research
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Chile
Santiago : Investigational Site Number 152005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Santiago : Investigational Site Number 152002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Santiago : Investigational Site Number 152004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Viña Del Mar : Investigational Site Number 152001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
China
Beijing : Investigational Site Number 156005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Beijing :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Chengdu :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Chongqing :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Guangzhou :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
View More »
Hangzhou :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Jinan :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Shanghai : Investigational Site Number
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Shanghai : Investigational Site Number 156003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Shanghai :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Tianjin :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Wuhan :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Czech Republic
Benesov : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brno : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brno : Investigational Site Number 203002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Hradec Králové : Fakultni nemo Hradec Králové
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Jindrichuv Hradec : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
View More »
Kromeriz : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Liberec : Krajská nemocnice Liberec a.s.
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Novy Jicin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Novy Jicin : Investigational Site Number 203003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Olomouc : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Olomouc : Investigational Site Number 203001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Praha 2 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Praha 2 : Investigational Site Number 203004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Praha 4 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Praha 6 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Usti nad Labem : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Zlin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Zlín : Krajská nemo. T.Bati, a. s.
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Znojmo : Nemocnice Znojmo
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Znojmo : Oddeleni Radiacni a Klinicke Onkologie Nemocnice Znojmo
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Denmark
Aalborg : Aalborg Sygehus
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Ålborg : Investigational Site Number 208004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Fredericia : Fredericia Hospital, Sygehus Lillebaelt
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Herlev : Investigational Site Number 208002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Herlev : Herlev Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Holstebro : Holstebro Sygehus
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kobenhavn : Rigshospitalet
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
København Ø : Investigational Site Number 208001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Odense C : Investigational Site Number 208003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Viborg : Regionhospitalet Viborg
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Finland
Helsinki : Investigational Site Number 246002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Helsinki : Docrates clinic
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Helsinki : Helsinki University Central Hospital
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Helsinki : Helsinki University Central Hospital
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Joensuu : Pohjois-Karjalan keskussairaala
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Kuopio : Investigational Site Number 246001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Kuopio : Kuopio University Hospital
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Kuopio : Kuopio University Hospital
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Tampere : Tampere University Hospital
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Tampere : Tampere University Hospital
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Turku : Investigational Site Number 246003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
France
Aix en Provence : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aix en Provence cedex 01 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amiens : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Angers : CHRU Angers
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Athis Mons : Centre Hospitalier d'Athis Mons site Caron
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Aubervilliers : Hopital Tenon
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Avignon : Investigational Site Number 250005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Avignon : Clinique Rhone Durance
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bayonne : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Besançon Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Besançon : CHU Saint-Jacques
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Besancon Cedex : Investigational Site Number 250010
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Bordeaux : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bordeaux Cedex : Investigational Site Number 250002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Bourg en Bresse : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brive la Gaillarde : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Caen Cedex 05 : Investigational Site Number 250006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Caen cedex 05 : Centre François Baclesse
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Clermont Ferrand : Centre Hospitalier Laennec
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Colmar Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Dijon cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Evry : Ramsay Sante
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Hyeres : Investigational Site Number 250008
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
La Roche Sur Yon : Investigational Site Number 250001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
La Seyne Sur Mer : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Le Mans Cedex 9 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Longjumeau cedex 1 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lyon : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Lyon : Investigational Site Number 250005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lyon : Groupement hospitalier Edouard Herriot
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Lyon cédex 08 : Centre Léon Bérard
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Marseille : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marseille : CHU Nord
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Marseille : Hopital de la Conception
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Marseille : Cabinet Médical 65 prado
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Melun : Polyclinique Saint-Jean
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Mont de Marsan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Montauban : Clinique du Pont de Chaume
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Montpellier : Clinique Beausoleil
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nancy : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nancy : Centre d'Urologie de Nancy
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nanterre : Hôpital Max Fourestier
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nantes Cedex 2 : Investigational Site Number 250002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Nice Cedex 2 : Centre Antoine Lacassagne
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Nimes : Investigational Site Number 250004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Nîmes : Groupe hospitalo-universitaire Caremeau
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Niort : Centre Hospitalier Georges Renon
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Orléans : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Périgueux cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Paris : Investigational Site Number 250010
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Paris :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Paris Cedex 05 : Investigational Site Number 250003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Paris Cedex 05 : Institut Curie
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Paris Cedex 10 : Investigational Site Number 250004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Paris Cedex 15 : Investigational Site Number 250001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Paris Cedex 20 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Paris Cedex 5 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Ploemeur : Clinique du Ter
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Poitiers Cedex : Investigational Site Number 250007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Poitiers Cedex : Centre Hospitalier Universitaire de Poitiers Hôpital de la Milétrie
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Pontoise : Clinic De L'Europe
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Pontoise Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pringy Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims : Investigational Site Number 250007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Reims : Investigational Site Number 250009
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Reims : Institut Jean-Godinot
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Reims Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rennes : Hopital Pontchaillou
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Rouen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Brieuc Cedex : Investigational Site Number 250006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Saint Grégoire cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Herblain : Institut de Cancérologie de l'Ouest - René Gauducheau
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Saint Quentin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soissons Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soyaux : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Strasbourg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Suresnes : Investigational Site Number 250008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Toulon : Clinique Saint Michel
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Toulouse : Clinique St Jean Languedoc
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Toulouse Cedex : Investigational Site Number 250003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Toulouse Cedex 03 : Investigational Site Number 250011
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Tours : Hopital Bretonneau
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Vandoeuvre les Nancy : CHU Brabois
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Vichy cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villefranche Sur Saone Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villejuif : Investigational Site Number 250001
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Villejuif : Investigational Site Number 250009
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Villejuif : Institut Gustave Roussy
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Villejuif :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Germany
Aachen : Investigational Site Number 276003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Aachen : Investigational Site Number 276003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Augsburg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bad Bergzabern : Praxis Dr. Schlichter
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bautzen : Praxis Dr. Markus Hentschel
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Berlin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Berlin : Investigational Site Number 276005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Braunschweig : Urologie im Schlosscarree
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bremerhaven : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bremerhaven : Praxis Dr. Ahmad Haider
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Chemnitz : Urologie Chemnitz
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Chemnitz : Praxis Dr. Krieger
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Dachau : Gemeinschaftspraxis fur Urologie
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Dinslaken : Klinikpraxis fur Urologie
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Dresden : Investigational Site Number 276007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Düsseldorf : Investigational Site Number 276004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Düsseldorf : Investigational Site Number 276001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Erlangen : Investigational Site Number 276001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Erlangen : Investigational Site Number 276004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Freiburg im Breisgau : Clinic SanaFontis
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
Goslar : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Halle/Saale : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Hamburg : Investigational Site Number 276005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hamburg : Investigational Site Number 276011
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hamburg : Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Hamburg : Praxis Dr. Schönfelder
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Homburg : Investigational Site Number 276010
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Homburg : Investigational Site Number 276002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Köln : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Kassel : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Kiel : Gemeinschaftspraxis Urologie
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kiel : Urologische Gemeinschaftspraxis
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kirchheim : Gemeinshaftspraxis Rudolph & Wörner
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Koln : Praxis Dr. Thomas Harms
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Leipzig : Vituro
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Mannheim : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marburg : Praxis Alexander von Keitz
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
München : Investigational Site Number 276006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
München : Investigational Site Number 276006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Neunkirchen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nienburg : Praxis Dr. Peczat
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nürtingen : Investigational Site Number 276012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Planegg : UCM GmbH
Treatment of Prostate Cancer With Firmagon®
Planneg : Studienzentrum München-Planegg
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Reutlingen : Urologische Gemeinschaftspraxis
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Rotenburg (Wümme) : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Stralsund : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Tostedt : Praxis Dr. Jan Franz
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Tübingen : Investigational Site Number 276008
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Würselen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wuppertal : Investigational Site Number 276002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Wuppertal : Praxis fur Urologie
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Greece
Alexandroupoli : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Athens : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Athens : "Agios Savas" Anticancer-Oncology Hospital of Athens
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Athens : Ippokrateio Hospital of Athens
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Athens : Korgialenio-Benakio
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Herakleion : Pe. Pa.G.N:I Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Heraklion : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kalamata : General hospital of Kalamata
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Larissa : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Larissa : University Hospital of Larissa
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Patra : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Patras : University General Hospital of Patras
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Thessaloniki : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Thessaloniki : Papageorgiou General Hospital of Thessaloniki
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Thessaloniki : "G. Gennimtas" General Hospital of Thessaloniki
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Hungary
Baja : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Budapest : Jahn Ferenc South Pest Hospital, Department of Urology
A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology
Budapest : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Budapest : Investigational Site Number 348001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Budapest : Investigational Site Number 348004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
View More »
Budapest : Investigational Site Number 348005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Budapest : Országos Onkológiai Intézet
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Budapest : Semmelweis Egyetem Általános Orvostudományi Kar
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Gyor : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Gyula : Pándy Kálmán Megyei Kórház
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Kiskunhalas : Kiskunhalasi Semmelweis Kórház Kht.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Miskolc : Investigational Site Number 348006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Miskolc : Borsod Abaúj Zemplén Megyei Kórház és Egyetemi Oktató Kórház
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Miskolc : Miskolci Semmelweis Ignác Egészségügyi Központ és Egyetemi Oktató Kórház Nonprofit Kft
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nyiregyhaza : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Pécs : Investigational Site Number 348003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sopron : Soproni Erzsébet Oktató Kórház
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Szeged : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
India
Ahmedabad : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Aurangabad : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Ludhiana : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Madurai : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nashik : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
View More »
New Delhi : Vardhaman Mahavir Medical College And Safdarjung Hospital
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Ireland
Dublin : Beacon Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Dublin : Beaumont Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Galway : University College Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Israel
Haifa : Bnai Zion medical center
A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy
Kfar Saba : Investigational Site Number 376004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Petah-Tikva : Investigational Site Number 376003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Tel Aviv : Investigational Site Number 376002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Tel Aviv : Ichilov Medical Center
Evaluation of the Safety and Efficacy of the BioProtect Balloon in Prostate Cancer Subjects Undergoing Radiotherapy
View More »
Tel Hashomer : Sheba Medical Center
Safety Evaluation of ExAblate MRgFUS for Prostate Cancer
Zerifin :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Italy
Arezzo : Investigational Site Number 380001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Avellino : Medical Consulting Center S.r.l.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Aviano :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Bari : Investigational Site Number 380004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Catanzaro : Azienda Ospedaliera Mater Domini di Catanzaro
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Cefalù PA : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Napoli : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Orbassano : Investigational Site Number 380003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Orbassano ( TO) : A.O. S. Luigi Gonzaga Updated
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
Padova : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Padova :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Pisa :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Ravenna :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Reggio Calabria : Azienda Ospedaliera "Bianchi-Melacrino-Morelli"
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Rimini :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Roma : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roma : Investigational Site Number 380005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Roma : Istituto Nazionale Tumori "Regina Elena"
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Rome :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Torino : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Torino : Azienda Ospedaliero Universitaria "San Giovanni Battista di Torino"
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Trento : Investigational Site Number 380002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Japan
Ageo-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Aichi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Akita : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Arakawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Asahi :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
View More »
Asahi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Asahikawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ashikaga : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Atsugi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Bunkyo-Ku : Investigational Site Number 392001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Chiba-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Chiba-Shi : Investigational Site Number 392003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Chigasaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Chikushino : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ebina : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Edogawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Eniwa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Fuji : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Fukuoka :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Fukuoka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Fukuoka-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Fukushima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Funahashi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Gifu :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Habikino : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hakusan : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hamada : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hamamatsu : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hidaka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hirosaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hiroshima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hitachi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Houmei : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ibaraki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ibi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ichihara : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ichikawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Iizuka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ikeda : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ikoma : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Inabe : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Inuyama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Isahaya : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Isesaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Itabashi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Izumisano : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kahoku : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kai : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kaizuka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kanazawa :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Kanazawa-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Kani : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kashiwa :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Kashiwa-Shi : Investigational Site Number 392006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Kasuga : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Katsushika : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kawagoe : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kawasaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kishiwada : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kita Kyushu : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kita-adachi-gun :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Kita-Gun :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Kobe : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kochi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Koshigaya : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Koto-Ku : Investigational Site Number 392005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Koutou : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kuki :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Kumamoto : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kurashiki :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Kurashiki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kurobe : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kurume : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kyoto : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Maebashi N/A :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Maebashi-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Matsushima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Matsuyama :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Matsuyama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Miki :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Minami Satsuma : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Minokamo : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Minoo : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Mitaka :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Mito : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Miyako : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Motiguchi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nagasaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nagoya : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nagoya-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Nakatsu : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nantan : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nara : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Narashino : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Natori : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Neyagawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nigata-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Niigata :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Niihama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nirasaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Numata : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ogaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Okayama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Okazaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Osaka :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Osaka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Osaka Sayama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Osaka Sayama-Shi : Investigational Site Number 392002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Osaka-City :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Osaka-Sayama :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Osaka-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Osaka-Shi : Investigational Site Number 392004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Ota : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sagamihara :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Sagamihara : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Saitama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sakai : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sakura :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Sakura : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sakura-Shi :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Sapporo :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Sapporo : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sasebo : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sashima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Seki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sendai : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Setagaya : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shibuya : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shimizu : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shinagawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shinjyuku : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shizuoka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shizuoka-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Suita : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Suita-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Sumida : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sunagawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tachikawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tagajo : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Takaoka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Takarazuka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Takasaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tokushima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tomakomai : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toride : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toshima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toyama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toyohashi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toyonaka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toyota : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tsu : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tsubame : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tsuchiura : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Uwajima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Wakayama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yamagata : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yamato : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yao : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yokohama :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Yokohama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yokohama-shi :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Yokosuka :
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Yoshinogawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yourou : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yukuhashi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Zentrsuji : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Korea, Republic of
Busan : Updated
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
Cheongju-Si : Updated
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
Gyenoggi-do :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Gyeonggi-do :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Jeonnam :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
View More »
Seognam-Si, Kyungki-Do : Updated
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
Seongnam : Investigational Site Number 410003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Seongnam : Seoul National University Bundang Hospital
Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy
Seoul :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Seoul : Investigational Site Number 410004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Seoul : Investigational Site Number 410005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Seoul : Investigational Site Number 410002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Seoul : Investigational Site Number 410001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Latvia
Jelgava : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Riga : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Malaysia
Kuala Lumpur :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Kuala Lumpur N/A :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Mexico
Acapulco : Investigational Site Number 484007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Aguascalientes : Investigational Site Number 484008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
D.f. : Investigational Site Number 484003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Distrito Federal : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Guadalajara : Investigational Site Number 484004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Merida : Investigational Site Number 484009
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Queretaro : Investigational Site Number 484005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
San Luis Potosi : Investigational Site Number 484002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Zapopan : Investigational Site Number 484006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Netherlands
Amstelveen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amsterdam : AMC
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Arnhem : Investigational Site Number 528005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Blaricum : Investigational Site Number 528003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Den Haag : MC Haaglanden
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Dordrecht : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Eindhoven : Catharina ziekenhuis
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Enschede : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Groningen : UMC Groningen
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients
Hoofddorp : Investigational Site Number 528004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Leiden : Diaconessenhuis Leiden
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Leiderdorp : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nieuwegein : St. Antonius Hospital Updated
Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.
Nijmegen : Investigational Site Number 528002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Nijmegen : UMC Nijmegen
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients
Nijmegen : Radboud University Nijmegen Medical Centre
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Purmerend : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roosendaal : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Utrecht : Diakonessenhuis Updated
Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.
Vlissingen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Zutphen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Zwolle : Investigational Site Number 528001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
New Zealand
Christchurch : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Takapuna, North Shore City : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Tauranga : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Whangarei : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Norway
Bergen : Haukeland Universitetssykehus
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Gjettum : Vestre Viken HF, Sykehuset Asker og Baerum
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Oslo : Oslo Universitetssykehus, Aker
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Oslo : Jon R Iversen
Treatment of Prostate Cancer With Docetaxel + Hormonal Treatment Versus Hormonal Treatment in Patients Treated With Radical Radiotherapy
Trondheim : Norwegian University of Science and Technology
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Peru
Arequipa : Investigational Site Number 604003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
View More »
Lima : Investigational Site Number 604005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Philippines
Quezon City, Metro Manila : Pfizer Investigational Site
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Poland
Bialystok : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bydgoszcz : Investigational Site Number 616002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Gdansk : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Gdansk : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gdansk : Investigational Site Number 616001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Gdynia : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Katowice : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Koscierzyna : Investigational Site Number 616003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Koszalin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krakow : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lodz : Investigational Site Number 616005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lubin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lubin : Investigational Site Number 616006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lublin : SPSK1 Klinika Hematologii
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Myslowice : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Olsztyn : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Olsztyn : Investigational Site Number 616002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Opole : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Poznan : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Poznan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Poznan : Investigational Site Number 616004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Rybnik : Investigational Site Number 616001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Siedlce : Investigational Site Number 616005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Slupsk : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Szczecin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Torun : Investigational Site Number 616004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Walbrzych : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Warszawa : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Warszawa : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wroclaw : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Wroclaw : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Portugal
Coimbra : Investigational Site Number 620003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lisboa : Investigational Site Number 620004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lisboa : Investigational Site Number 620005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Porto : Investigational Site Number 620001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Porto : Investigational Site Number 620002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Puerto Rico
Ponce :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Romania
Alba Iulia : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Alba Iulia : Investigational Site Number 642005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Baia Mare : Investigational Site Number 642006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Baia Mare : Investigational Site Number 642004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Baia-Mare : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Brasov : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucharest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucharest : Investigational Site Number 642008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Bucuresti : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucuresti : Investigational Site Number 642008
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bucuresti : Investigational Site Number 642009
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bucuresti : Investigational Site Number 642005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Bucuresti : Centrul de Diagnostic si Tratament Euromedic Fundeni
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Cluj Napoca : Investigational Site Number 642001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Cluj-Napoca : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Focsani : Investigational Site Number 642012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hunedoara : Investigational Site Number 642007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hunedoara : Investigational Site Number 642007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Onesti : Investigational Site Number 642013
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Oradea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ramnicu Valcea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Targu Mures : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Timisoara : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Russian Federation
Ekaterinburg : Investigational Site Number 643009
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Ekaterinburg : Investigational Site Number 643004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Ekaterinburg :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Ivanovo : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Moscow : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
View More »
Moscow : Investigational Site Number 643004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Moscow : Investigational Site Number 643005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Moscow : Investigational Site Number 643006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Moscow : Investigational Site Number 643007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Moscow : Investigational Site Number 643008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Moscow :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Moscow N/A :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Nizhny Novgorod : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Obninsk : Investigational Site Number 643008
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Omsk : Investigational Site Number 643003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Pyatigorsk : Investigational Site Number 643002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Pyatigorsk :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Rostov-na-Dony : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Rostov-On-Don :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Ryazan : Investigational Site Number 643007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Sochi :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
St.Petersburg : Investigational Site Number 643001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
St.Petersburg : Investigational Site Number 643010
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Stavropol :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
St-Petersburg : Investigational Site Number 643005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Tomsk : Investigational Site Number 643001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Tula : Investigational Site Number 643003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Ufa :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Yaroslavl : Investigational Site Number 643006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Yoshkar-Ola :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Slovakia
Bosany : VEBMED, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bratislava : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Bratislava : URO clinic, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bratislava : CUIMED, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bratislava : Univerzitna nemocnica Bratislava
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Galanta : Poliklinika Galanta
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kosice : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kosice : MEDICONA s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Levice : UROCENTRUM LEVICE, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Malacky : Poliklinika Malacky
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Martin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Martin : Univerzitna nemocnica Martin
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nitra : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nitra : UROEXAM, spol. s r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Povazska Bystrica : CENTRUM UROLOGIE Povazska Bystrica s.r.o
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Presov : MILAB, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Sala : UROCENTRUM SALA, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Skalica : Nemocnica s poliklinikou Skalica, a.s.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Topolcany : M & M & M, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Trencin : PRIVATNA UROLOGICKA AMBULANCIA s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Vrable : UROREX, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Slovenia
Celje : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Ljubljana : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Slovenj Gradec : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
South Africa
Cape Town : Investigational Site Number 710003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cape Town : Department of Urology, Tygerberg Hospital
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Cape Town : New Grootte Schuur Hospital, Division of Urology
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Cape Town : Paarl Medical Centre
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Cape Town : Vergelegen Medi-Clinic
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
View More »
Durban : Investigational Site Number 710002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Eastern Cape : Dr JCM Bahlmann
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Gauteng : Pretoria Urology Hospital
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Gauteng : Clinical Trial Unit, Room 2-54, Prinshof Medical Campus
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Gauteng : Clinresco Centres (Pty) Ltd
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
George : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Johannesburg : Investigational Site Number 710004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Johannesburg : Investigational Site Number 710005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Johannesburg : East Rand Urology Research Unit, Clinix Private Clinic
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Kempton Park : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Klerksdorp : Wilmed Park Hospital
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Paarl : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Port Elizabeth : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Pretoria : Investigational Site Number 710001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Tygerberg : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Spain
Badalona : Investigational Site Number 724003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Barcelona : Investigational Site Number 724001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Barcelona : Investigational Site Number 724007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Barcelona : Investigational Site Number 724001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Barcelona : Investigational Site Number 724002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Barcelona : Hospital Clinic i Provincial de Barcelona
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Barcelona : H. de la Santa Creu i Sant Pau Updated
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
Barcelona : Fundación IMOR Updated
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
Hospitalet De Llobregat : Investigational Site Number 724003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Hospitalet de Llobregat : ICO Institut Català d'Oncologia-Hospitalet Updated
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
Madrid : Investigational Site Number 724008
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Madrid : Investigational Site Number 724002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Madrid : Investigational Site Number 724004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Madrid : Investigational Site Number 724005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Madrid : H. Ramón y Cajal Updated
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
Málaga : Investigational Site Number 724006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Palma De Mallorca : Investigational Site Number 724005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sabadell : Investigational Site Number 724004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
San Sebastián : Instituto Oncológico Updated
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
Santiago De Compostela : Investigational Site Number 724006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Sevilla : Investigational Site Number 724007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Valencia : IVO Instituto Valenciano de Oncología Updated
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
Valencia : Private practice, La Cañada, Paterna Updated
Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State
Sweden
Goteborg :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Malmo :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Malmö : Investigational Site Number 752003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Malmoe : Urology Dep. Skane Univeristy Hospital
Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer
Orebro :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
View More »
Stockholm : Investigational Site Number 752002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Stockholm :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Umea :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Uppsala : Investigational Site Number 752001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Uppsala : Department of Oncology, University Hospital Uppsala
Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer
Uppsala :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Vaxjo :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Switzerland
Basel : Universitätsspital Basel
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Genolier : IMO Clinique de Genolier
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Lausanne : Centre Hospitalier Universitaire Vaudois
Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer
Zurich : Urozentrum Zürich
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Taiwan
Kaohsiung : Investigational Site Number 158004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Taiching : Investigational Site Number 158002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Taichung : Investigational Site Number 158002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Taichung City : Updated
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
Taipei : Pfizer Investigational Site
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
View More »
Taipei : Investigational Site Number 158001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Tao-Yuan : Investigational Site Number 158003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Taoyuan County : Updated
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
Thailand
Bangkok :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Tunisia
Ariana : Investigational Site Number 788001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sfax : Investigational Site Number 788004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sousse : Investigational Site Number 788003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Tunis : Investigational Site Number 788002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Turkey
Ankara : Investigational Site Number 792002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Antalya : Investigational Site Number 792003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bornova : Investigational Site Number 792001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Istanbul : Investigational Site Number 792002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Istanbul : Investigational Site Number 792001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Kayseri : Investigational Site Number 792004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Ukraine
Cherkasy : Investigational Site Number 804009
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Dnipropetrovsk : Investigational Site Number 804004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Donetsk : Investigational Site Number 804010
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Ivano-Frankivsk : Investigational Site Number 804006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Kharkov : Investigational Site Number 804003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Kyiv : Investigational Site Number 804001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Kyiv : Investigational Site Number 804002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lutsk : Investigational Site Number 804007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Uzhgorod : Investigational Site Number 804005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Zaporizhzhya : Investigational Site Number 804008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
United Kingdom
Addlestone : The Crouch Oak Family Practice Updated
GP Extended Action Triptorelin
Ashford : Dr Carter & Partners Updated
GP Extended Action Triptorelin
Aylesbury : Westongrove Research Centre, Aston Clinton Surgery Updated
GP Extended Action Triptorelin
Bath : Clinical Research Unit, Oldfield Surgery Updated
GP Extended Action Triptorelin
Bath : Clinical Research Unit, The Pulteney Practice Updated
GP Extended Action Triptorelin
View More »
Bath : St James' Surgery Updated
GP Extended Action Triptorelin
Birmingham : Investigational Site Number 826002
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Birmingham : Queen Elizabeth Hospital
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Birmingham : Queen Elizabeth Hospital
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Blackpool : Waterloo Medical Centre Updated
GP Extended Action Triptorelin
Bury St. Edmunds : Woolpit Health Centre Updated
GP Extended Action Triptorelin
Canterbury : Cossington House Surgery Updated
GP Extended Action Triptorelin
Cardiff : Velindre Cancer Centre
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Cardiff : Velindre Cancer Centre
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Chesterfield : Research Office, Avondale Surgery Updated
GP Extended Action Triptorelin
Chippenham : Clinical Research Dept., Rowden Surgery Updated
GP Extended Action Triptorelin
Chippenham : Clinical Research Unit, Hathaway Medical Centre Updated
GP Extended Action Triptorelin
Colchester : Investigational Site Number 826004
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Corsham : The Porch Surgery Updated
GP Extended Action Triptorelin
Crawley : Pound Hill Surgery Updated
GP Extended Action Triptorelin
East Horsley : The Medical Centre Updated
GP Extended Action Triptorelin
Glasgow : Investigational Site Number 826005
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Guildford : Investigational Site Number 826006
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hinckley : Burbage Surgery Updated
GP Extended Action Triptorelin
Hitchin : The Portmill Surgery Updated
GP Extended Action Triptorelin
Irvine : Townhead Surgery Updated
GP Extended Action Triptorelin
Leamington Spa : Sherbourne Medical Centre Updated
GP Extended Action Triptorelin
London : Royal Marsden Foundation Trust Instute of Cancer Researrch
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
London : University College London Hospitals
Imaging for Significant Prostate Cancer Risk Evaluation
London : Royal Marsden Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
London : Kings College Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
London : Whipps Cross Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
London : Homerton University Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
London : Royal Marsden NHS Foundation Trust
Prostate Advances in Comparative Evidence
London : Barts Cancer Institute - a Cancer Research UK Centre of Excellence, Queen Mary University of London
Sipuleucel-T Manufacturing Demonstration Study
Manchester : Pfizer Investigational Site
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Manchester : Investigational Site Number 826007
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Manchester : Christie Hospital
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Manchester : Christie Hospital
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Mortimer : Mortimer Surgery Updated
GP Extended Action Triptorelin
Nantwich : Kiltearn Medical Centre Updated
GP Extended Action Triptorelin
Newcastle Upon Tyne : Investigational Site Number 826003
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Northampton : Kingsthorpe Medical Centre Updated
GP Extended Action Triptorelin
Northampton : Danes Camp Surgery Updated
GP Extended Action Triptorelin
Oxford : Churchill Hospital
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Oxford : Churchill Hospital
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Penzance : Cape Cornwall Surgery Updated
GP Extended Action Triptorelin
Penzance : The Alverton Practice Updated
GP Extended Action Triptorelin
Peterborough : Wansford & Kings Cliffe Practice, Wansford Surgery Updated
GP Extended Action Triptorelin
Plymouth : The Rame Group Practice Updated
GP Extended Action Triptorelin
Plymouth : Knowle House Surgery Updated
GP Extended Action Triptorelin
Plymouth :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Redhill : East Surrey Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Rotherham : The Rotherham NHS Foundation Trust - Dept. of Haematology
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Sandbach : Ashfields Primary Care Centre Updated
GP Extended Action Triptorelin
St Austell : Brannel Surgery Updated
GP Extended Action Triptorelin
Sunbury-on-Thames : Sunbury Health Centre Group Practice Updated
GP Extended Action Triptorelin
Sunderland : Sunderland Royal Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Surrey : The Royal Marsden Hospital
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Sutton : Royal Marsden Foundation Trust Instute of Cancer Research
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Sutton : Investigational Site Number 826001
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Sutton : Investigational Site Number 826001
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sutton :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Sutton :
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Trowbridge : Adcroft Surgery Updated
GP Extended Action Triptorelin
Watford : Sheepcot Medical Centre Updated
GP Extended Action Triptorelin
Wellingborough : Albany House Medical Centre Updated
GP Extended Action Triptorelin
Wokingham : Woosehill Medical Centre Updated
GP Extended Action Triptorelin
